ClinicalTrials.gg
CompletedNCT00074737Updated Sep 18, 2014

Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML

A Phase 2 interventional study of cenersen and Idarubicin in Acute Myelogenous Leukemia, sponsored by Eleos, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-18.

Sponsored by Eleos, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 247 studies testing cytarabine in Leukemia, Myeloid, Acute — 39 open to participants now, 45 under way, 10 of them phase 3. Cytarabine · Leukemia, Myeloid, Acute.

Enrollment
106th of 239
53 · median 48
Started
2004
with 10 others
Phase 2
112 of 247
21 open now
Registered
29th of 247
by date

Among the 247 studies testing cytarabine in Leukemia, Myeloid, Acute, this one is the 106th largest by enrollment of the 239 interventional ones that give a count, is one of 11 that started in 2004, is one of 112 in phase 2, and was the 29th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

39 of the 247 studies testing cytarabine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

34 more — sign in →

By country, each count listing its studies:

All 39 open studies →

About cytarabine

Cytarabine: first FDA approval 1969 (CYTARABINE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies testing cytarabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The principal goal of this clinical trial is to assess the ability of cenersen sodium (EL625) to improve cancer responsiveness to the established AML therapeutic agent Idarubicin used alone or in combination with Cytarabine (Ara-C).

Cenersen sodium is a drug that is designed to block the effects of a protein called p53. Laboratory evidence shows that blocking p53 will make many types of cancer, including acute myelogenous leukemia (AML), more sensitive to a variety of established cancer therapeutics while making normal tissues more resistant to the toxic effects of these agents.

Read the detailed description

This clinical trial is designed to assess the ability of cenersen sodium (EL625) in combination with Idarubicin alone or with Cytarabine to either: (1) induce remissions in patients who have previously failed to go into remission in response to chemotherapy; or (2) provide patents who have relapsed after going into a chemotherapy-induced remission with a longer remission.

Cenersen sodium is one of a new class of drugs called antisense oligonucleotides (oligos). Oligos are designed to block the production of specific proteins and thereby inhibit their function. Cenersen sodium targets p53, a widely studied protein.

In cancer, p53 occurs either in the un-mutated ("normal") or mutated forms. The majority of participants in this trial are expected to have un-mutated p53. Cenersen sodium is anticipated to sensitize cancers with un-mutated p53 to most established cancer therapeutics.

p53 has a pivotal role in protecting the body from cells that have suffered genetic damage and, as a result, do not function properly. The protein first senses the level of the damage and then forces the damaged cell to respond to the damage either by repairing itself or committing suicide. In general, the greater the level of damage the more likely the cellular response will be suicide.

Many cancer therapeutics, including both chemotherapy and radiation, cause the types of genetic damage that activate p53 and, consequently, cause either damage repair or cellular suicide. Laboratory studies suggest that cancer cells have a host of defenses that reduce the chances that these cells will respond to genetic damage by committing suicide. So compared to normal cells, cancer cells are more likely to repair the damage caused by cancer therapeutics while normal cells are more likely to commit suicide. Thus, blocking un-mutated p53 is more likely to prevent repair in cancer cells while preventing suicide in normal cells. This provides the basis for a differential effect of cenersen sodium on cancer cells verses normal cells.

When p53-dependent repair is prevented in cancer cells they begin to copy their damaged genetic information in preparation for cell division. This copying of the genetic damage triggers a p53-independent backup suicide mechanism and, as a result, the cancer cells are eliminated. This is the presumed mechanism whereby cenersen sodium is able to sensitize cancer cells with normal p53 function to numerous cancer therapeutics.

At higher doses however, chemotherapy sometimes blocks cells from copying their genes in preparation for division. Thus, it is possible that a chemotherapeutic agent used at a high dose could block any sensitizing effect that cenersen sodium might otherwise have on the cancer.

The chemotherapeutic agent Idarubicin is known to produce the type of genetic damage that effects p53 expression, causes p53-dependent responses and has been shown to be made more effective at killing cancer cells by cenersen sodium. Cytarabine (Ara-C) is the most widely used chemotherapeutic agent for AML. Cenersen sodium does not appear to sensitize cancer cells to Cytarabine and at higher doses Cytarabine may reduce the capacity of cenersen sodium to sensitize cancer cells.

Hence, this AML study will examine the effects of Cenersen sodium used in combination with Idarubicin and one of three different doses of Cytarabine (i.e. 0, 0.1 and 1.0 gm/m2/day), on the responsiveness of participants to these chemotherapeutic agents.

03

Conditions studied

  • Acute Myelogenous Leukemia

Keywords

  • Refractory or Relapsed Acute Myelogenous Leukemia (AML)
  • Antisense
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with either AML (not achieving a CR after a single course of induction), or relapsed AML that have a CR for less than one year.
  • greater or equal to 18 years old.
  • of more than 4 weeks following initiation of treatment.
  • Performance status (Zubrod) less or equal to 3.
  • Total less or equal to 1.5 x upper normal limit (UNL) unless attributable to organ infiltration by leukemia, and (SGPT) less or equal to 2.5 x UNL.
  • Creatinine less or equal to 1.5 x UNL unless attributable to organ infiltration by leukemia.
  • If plasma creatinine value is borderline, greater or equal to 60 ml/min (actual or calculated), serum magnesium should be within the normal value.
  • Subjects with liver and/or renal dysfunction due to organ infiltration by leukemia are eligible.
  • Left Ventricular Ejection Volume () of >50% as determined by multi-gated acquisition scan (MUGA) or echocardiogram.
  • Able to comply with scheduled follow-up and with management of toxicity.
  • Sexually active patients must use an effective method of during the study dosing period. The following are considered acceptable methods of contraception: (i) oral contraceptive pill, (ii) condom, (iii) diaphragm plus spermicide, (iv) patient or partner surgically sterile, (v) patient or partner more than 2 years or (vi) injectable or implantable agent/device.
  • form obtained, signed and dated prior to initiation of treatment

Exclusion criteria

Exclusion Criteria:

  • Subjects with M3 AML.
  • Subjects receiving other anti-leukemia agents (i.e., unapproved drugs). However, individual cases will be considered on a case-by-case basis for other investigational agents (e.g., antibiotics, antifungals).
  • Pregnant or lactating subjects. Chemotherapy (including hydroxyurea) within three (3) weeks prior to initiation of therapy, unless there is evidence of rapidly progressive disease; then subjects may be enrolled with a minimum of two (2) weeks from previous treatments.

Prohibited Medications during the first week of each course:

  • Acetaminophen
  • Hi-Dose antioxidants (e.g., Vitamins C, E; Multivitamins)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Active comparator
    cenersen, idarubicin

    cenersen, idarubicin, no cytarabine

    Drug: cenersen · Drug: Idarubicin

  • Active comparator
    cenersen, idarubicin, cytarabine

    cenersen, idarubicin, standard dose cytarabine

    Drug: cenersen · Drug: Idarubicin · Drug: Cytarabine

  • Active comparator
    cenersen, idarubicin, HDAC

    cenersen, idarubicin, HDAC (high dose cytarabine)

    Drug: cenersen · Drug: Idarubicin · Drug: Cytarabine

Interventions

  • cenersen with standard of care

    Also known as: cenersen sodium, Ol(1)p53, EL625, Aezea

  • standard of care for AML

    Also known as: idamycin

  • standard of care Ara-C and High dose Ara-C

    Also known as: Ara-C, HDAC

06

What researchers measure

Primary outcomes

  1. Determine the effective dose of Cytarabine chemotherapy to be used in combination with EL625 and Idarubicin.

    Cenersen plus standard of care

    Time frame: 6 months

Secondary outcomes

  1. Determine the safety profile for the combination of EL625 and Idarubicin +/- Cytarabine.

    Standard of care plus cenersen

    Time frame: 6 months

  2. Determine the Complete Response Rate and Time to Progression.

    Standard of care plus cenersen

    Time frame: 6 months

07

Study locations

6 sites
  • University of California, San Diego
    La Jolla, California 92093-0960, United States
  • University of Miami Health Center
    Miami, Florida 33136, United States
  • Washington University Medical Center (Siteman Cancer Center)
    St. Louis, Missouri 63110, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • North Shore University Hospital
    Lake Success, New York 11041, United States
  • M. D. Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of May 2007 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2003
First posted
Dec 23, 2003
Start
Apr 2004
Primary completionActual
May 2007
CompletionActual
May 2007
Last update
Sep 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00074737
Lead sponsor
Eleos, Inc.
Responsible party
Sponsor
First posted
Dec 23, 2003
Start date
Apr 2004
Primary completion
May 2007
Completion
May 2007
Last update
Sep 18, 2014

Study contacts

Jorge E Cortes, MD
principal investigator · M.D. Anderson Cancer Center
Edward D. Ball, MD
principal investigator · University of California, San Diego
John DiPersio, MD
principal investigator · Washington University Medical Center, Siteman Cancer Center
Maria Baer
principal investigator · Roswell Park Cancer Institute
Jonathan Kolitz, MD, FACP
principal investigator · North Shore University Hospital
Hugo Fernandez, MD
principal investigator · University of Miami

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytarabine

Start the discussion